Cytyc UK boosted by regio's ThinPrep LBC decision:
This article was originally published in Clinica
Cytyc UK's bid to increase its stake in the national cervical screening market received a boost this week, following the decision by the Southwest region of the National Health Service (NHS) to use the company's ThinPrep liquid-based cytology (LBC) test in all its cervical screening programmes. The decision is to be implemented in all the region's 13 laboratories, which perform some 360,000 tests a year. Over the next five years, these will total an estimated 1.8 million tests. The decision follows a pilot implementation project at Bristol's Southmead Hospital. The technology also received the approval in August 2003 of the National Institute for Clinical Excellence (see Clinica No 1071, p 5). NHS Southwest incorporates the Strategic Health Authorities of Avon, Gloucester & Wiltshire, Devon & Somerset and the South West Peninsula.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.